Publications and Patents


  1. Vandenbroeke T, Gloor C, Wingfield T, Leite C, Carr K, Turner C, Ngamsuntikul S, Sutor L, Compton F, Nestheide S, Rugg N, Cancelas JA, Dumont LJ. In vitro quality parameters of whole blood-derived platelets pooled using two different platelet pooling sets and stored up to 7 days are similarTransfusion 2023 Nov 22.doi: 10.1111/trf.17591. Online ahead of print. PMID  37991217
  2. Solomon M, Song B, Govindarajah V, Good S, Arasu A, Hinton EB, Thakkar K, Bartram J, Filippi M-D, Cancelas JA, Salomonis N, Grimes HL, Reynaud D. Slow cycling and durable Flt3+ progenitors contribute to blood production under native conditionsJ Exp Med 2024 Jan 1;221(1):320231035. Doi: 10.1084/jem.20231035. Epub 2023 Nov 1. PMID 37910046 PMC10620607 (available on 2024-05-01)
  3. Thant M, Cancelas J, Kaplan A. The enhanced direct antiglobulin test in current practice has a limited impact on management of adult patientsTransfus Apher Sci 2023 Aug 17: 103768. doi: 10.1016/j.transci.2023.103768. Online ahead of print. PMID: 37599155
  4. Dandamudi A, Seibel W, Tourdot B, Cancelas J, Huzoor A, Zheng Y. Structure–activity relationship analysis of rhosin, a rhoA GTPase Inhibitor, reveals a new class of antiplatelet agentsInt J Mol Sci 2023 Feb;24(4):4167. doi:10.3390/ijms24044167 PMID 36835579 PMC9961652 
  5. Dandamudi A, Huzoor A, Cancelas J, Zheng Y. Rho GTPase signaling in platelet regulation and implication for antiplatelet therapiesInt J Mol Sci 2023 Feb;24(3):2519. DOI:10.3390/ijms24032519 PMID: 36768837 PMC9917354
  6. Galletta TJ, Lane A, Lutzko C, Leemhuis T, Cancelas JA, Khoury R, Wang YM, Hanley PJ, Keller MD, Bollard CM, Davies SM, Grimley MS, Rubinstein JD. Third party and patient-specific donor-derived virus-specific T cells demonstrate similar efficacy and safety for management of viral infections after hematopoietic stem cell transplant in children and young adults. Transplant Cell Ther May 2023;29(5):305-310. PMID: 36736781
  7. Butler-Foster T, Khandelwal A, Montemayor C, Miller YM, Yan MTS, Holmberg JA, Ipe TS, Accooe P, Cancelas JA; (the AABB Diversity, Equity, Inclusion, and Access Task Force). From MPOX to the next epidemic: Words matter when talking about equity-deserving groupsTransfusion. 2023;63(3):646-651. Epub Feb 8 2023. doi: 10.1111/trf.17270. PMID: 36756669 (Commentary)
  8. Menéndez-Gutiérrez MP*, Porcuna J, Nayak R, Paredes A, Niu H, Núñez V, Paranjpe A, Gómez MJ, Bhattacharjee A, Schnell DJ, Sánchez-Cabo F, Welch JS, Salomonis N, Cancelas*, Ricote M. Retinoid X receptor promotes hematopoietic stem cell fitness and quiescence and preserves hematopoietic homeostasis. Blood. 2023 Feb 9;141(6):592-608. PMID: 36347014. PMC10082360 (available on 2024-02-09) (*Co-corresponding authors).
  9. Hegde S, Zheng Y, Cancelas JA. Novel blood derived hemostatic agents for bleeding therapy and prophylaxisCurr Opin Hematol. 2022 Nov;29(6):281-289. Epub Aug 4, 2022. doi: 10.1097/MOH.0000000000000737. PMID: 35942861.
  10. Cancelas JA, Genthe JR, Stolla M, Rugg N, Bailey SL, Nestheide S, Shaz B, Mack S, Schroeder K, Anani W, Szczepiorkowski ZM, Dumont LJ, Yegneswaran S, Corash L, Mufti N, Benjamin RJ, Erickson AC. Evaluation of amotosalen and UVA pathogen-reduced apheresis platelets after 7-day storageTransfusion. 2022 Aug;62(8):1619-1629. PMID: 35808974. PMC9546462
  11. Vogel M, Möhrle B, Sakk V, Brown A, Palmer A, Braumüller S, Huber-Lang M, Allgöwer A, Cancelas JA, Geiger H. A limited role for AMD3100 induced stem cell mobilization for modulation of thoracic trauma outcomeShock. 2022 Jun 1;57(6):260-267. PMID: 35759306
  12. Nayak RC, Chang K, Singh AK, Kotlian M, Desai M, Wellendorf AM, Wunderlich M, Bartram J, Mizukawa B, Cuadrado M, Dexheimer P, Barski A, Bustelo XR, Nassar NN, Cancelas JA. Nuclear Vav3 is required for polycomb repression complex-1 activity in B-cell lymphoblastic leukemogenesisNat Commun 2022 Jun 1;13(1):3056. PMID: 35650206 PMC9160250
  13. Patritti Cram J, Wu J, Coover RA, Rizvi TA, Chaney KE, Ravindran R, Cancelas JA, Spinner RJ, Ratner N. Purinergic receptor P2RY14 cAMP signaling regulates Schwann cell precursor self-renewal, Schwann cell proliferation, and nerve tumor initiation in a mouse model of neurofibromatosisElife 2022 Mar 21;11:e73511. doi: 10.7554/eLife.73511. PMID: 35311647 PMC8959601
  14. Mock DM, Stowell SR, Franco RS, Kyosseva SB, Nalbant D, Schmidt RL, Cres GA, Strauss RG, Cancelas JA, von Goetz M, North AK, Widness JA. Antibodies against biotin-labeled red blood cells can shorten posttransfusion survival. Transfusion 2022 Apr;62(4):770-782  PMID: 35274303 PMC9007277
  15. Hegde S, Gasilina A, Wunderlich M, Lin Y, Buchholzer M, Krumbach OHF, Akbarzadeh M, Ahmadian MR, Seibel W, Zheng Y, Perentesis JP, Mizukawa BE, Vinnedge LP, Cancelas JA, Nassar NN. Inhibition of the RacGEF VAV3 by the small molecule IODVA1 impedes RAC signaling and overcomes resistance to tyrosine kinase inhibition in acute lymphoblastic leukemiaLeukemia. 2022 Mar;36:637-647. PMID: 34711926 PMC8885421 
  16. Rubinstein JD, Lutzko C, Leemhuis T, Zhu X, Pham G, Ray LM, Thomas S, Dourson C, Wilhelm J, Lane A, Cancelas JA, Lipps D, Ferrell J, Hanley PJ, Keller MD, Bollard CM, Wang YM, Davies SM, Nelson AS, Grimley M. Scheduled administration of virus-specific T cells for viral prophylaxis after pediatric allogeneic stem cell transplantBlood Adv May 10, 2022;6(9):2897-2907. PMID: 35108727 7 PMC9092421 
  17. Noel JG, Ramser SW, Pitstick L, Bonamer JP, Mackenzie B, Seu KG, Kalfa TA, Cancelas JA, Gardner JC. M-CSF supports medullary erythropoiesis and erythroid iron demand following burn injury through its activity on homeostatic iron recyclingSci Rep. 2022 Jan 24;12(1):1235. PMID: 35075211 PMC8786861 
  18. Cancelas JA, Nestheide S, Rugg N, Eckerman A, MacDonald VW, Charles ML, Markstrom L, Atkinson AJ, King MR, Snyder M, Burgess D, Murto J, Valiyaveettil MK, Pehta JC, Penegon SA. Characterization and first-in-human clinical dose-escalation safety evaluation of a next-gen human freeze-dried plasmaTransfusion Feb 2022;62(2)406-17. PMID: 34951486
  19. Rubinstein JD, Jodele S, Heyenbruch D, Wilhelm J, Thomas S, Lutzko C, Zhu X, Leemhuis T, Cancelas JA, Keller M, Bollard CM, Hanley PJ, Boghdadly ZE, Mims A, Davies SM, Grimley MS, Nelson AS. Off the shelf third party virus specific T-cell therapy to treat JC polyomavirus infection in hematopoietic stem cell transplant recipientsTransplant Cell Ther 2022 Feb;28(2):116.e1-116.e7. PMID: 34785398
  20. Ohanian M, Cancelas JA, Davenport R, Pullarkat V, Hervig T, Broome C, Marek K, Kelly M, Gul Z, Rugg N, Nestheide S, Kinne B, Szczepiorkowski Z, Kantarjian H, Pehta J, Biehl R, Yu A, Aung F, Antebi B, Fitzpatrick GM. Freeze-dried platelets are a promising alternative in bleeding thrombocytopenic patients with hematological malignanciesAm J Hematol 2022 Mar 1;97(3):256-266. PMID: 34748664
  21. Rubinstein JD, Zhu X, Leemhuis T, Pham G, Ray L, Emberesh S, Jodele S, Thomas S, Cancelas JA, Bollard CM, Hanley PJ, Keller MD, Grimley O, Clark D, Clark T, Lindestam Arlehamn CS, Sette A, Davies SM, Nelson AS, Grimley MS, Lutzko C. Virus-specific T cells for adenovirus infection after stem cell transplantation are highly effective and class II HLA restrictedBlood Adv. 2021 Sep 14;5(17):3309-3321. PMID: 34473237 PMC8525242
  22. Adori C, Daraio T, Kuiper R, Barde S, Horvathova L, Yoshitake T, Ihnatko R, Valladolid-Acebes I, Vercruysse P, Wellendorf AM, Gramignoli R, Bozoky B, Kehr J, Theodorsson E, Cancelas JA, Mravec B, Jorns C, Ellis E, Mulder J, Uhlén M, Bark C, Hökfelt T. Disorganization and degeneration of liver sympathetic innervations in nonalcoholic fatty liver disease revealed by 3D imagingSci Adv. 2021 Jul 21;7(30):eabg5733. PMID: 34290096 PMC8294768. (The protocol for this paper may be requested at Request a Protocol - Bio-protocol)
  23. Fan Y, Teng Y, Loison F, Pang A, Kasorn A, Shao X, Zhang C, Ren Q, Yu H, Zheng Y, Cancelas JA, Manis J, Chai L, Park SY, Zhao L, Xu Y, Feng S, Silberstein LE, Ma F, Luo HR. Targeting multiple cell death pathways extends the shelf life and preserves the function of human and mouse neutrophils for transfusionSci Transl Med. 2021 Jul 28;13(604):eabb1069. PMID: 34321317 PMC10336857/
  24. Serrano-Lopez J, Hegde S, Kumar S, Serrano J, Fang J, Wellendorf AM, Roche PA, Rangel Y, Carrington LJ, Geiger H, Grimes HL, Luther S, Maillard I, Sanchez-Garcia J, Starczynowski DT, Cancelas JA. Inflammation rapidly recruits GMP and MDP from bone marrow into regional lymphaticsElife 2021 Apr 8;10:e66190 PMID:33830019  PMC8137144 
  25. Davis G, York AJ, Bacon WC, Lin SC, McNeal MM, Yarawsky AE, Maciag JJ, Miller JLC, Locker KCS, Bailey M, Stone R, Hall M, Gonzalez J, Sproles A, Woodle ES, Safier K, Justus KA, Spearman P, Ware RE, Cancelas JA, Jordan MB, Herr AB, Hildeman DA, Molkentin JD. Seroprevalence of SARS-CoV-2 infection in Cincinnati Ohio USA from August to December 2020PLoS One 2021 Jul 14;16(7):e0254667. PMID: 34260645  PMC8279307
  26. Singh AK, Cancelas JA. Mitochondria transfer in bone marrow hematopoietic activityCurr Stem Cell Rep 2021 Mar;7:1-12. PMID: 36846725 PMC9956307
  27. Hegde S, Wellendorf A, Zheng Y, Cancelas JA. Antioxidant prevents clearance of hemostatically competent platelets after long-term cold storageTransfusion. 2021 Feb;61(2):557-567. PMID: 33247486. PMC8006927
  28. Prus K, Alquist CR, Cancelas JA, Oh D. Decrease in serum antibodies to SARS-CoV-2 in convalescent plasma donors over time. Transfusion 2021 Feb;61(2):651-4. PMID: 33616966 PMC8014079


Platelet Storage Methods and Compositions for Same. Zheng Y, Cancelas J.

US Patent 10405538 September 10, 2019. Publication: US010405538B2

Platelet Storage Methods and Compositions for Same. Zheng Y, Cancelas J.

US Patent 10028503 B2 July 24, 2018. Publication US010028503B2 Jul 24, 2018; US 2018/0139952 A1 May 24, 2018

Compositions and methods for slowing, preventing, or reversing platelet damage, particularly as may occur during blood banking or during refrigeration of platelets. The composition may include one or more of a RAC inhibitor, a CDC42 inhibitor, a RHOA inhibitor, or a combination thereof. The compositions may further include a pharmaceutically acceptable carrier.

Prolonged Storage of Red Blood Cells and Composition. Hess JR, Greenwalt TJ

Issue Date: November 21, 2000, US Patent # 6150085

Novel additive solutions that are useful for the storage of human red blood cells (RBCs) under refrigerated conditions. Also, a method of using the additive solutions in an appropriate volume to preserve RBCs at about 1 to 6°C for up to 10 weeks. The solutions and processes allow the viable storage of human RBCs for an extended period of time in a solution which is directly infusible in humans.

Preservation and Shelf Life Extension of Blood Cells. Hess JR, Greenwalt TJ

Issue Date: November 20, 2001, US Patent # 6447987

Preservative solutions that extend the useful shelf-life of red cells from the current 6 to 12 weeks. This intellectual property is shared by the US Army and the University of Cincinnati. Implementation is expected to save 600,000 units from outdating annually, to reduce seasonal shortages of blood, and to make autologous donor programs more efficient.

Compositions Substantially Free of Sodium Chloride and Methods For The Storage of Red Blood Cells. Hess JR, Greenwalt TJ

Issue Date: April 29, 2014, US Patent # 8709707

Composition of a solution for storage of red blood cells consisting essentially of: adenine; dextrose; a non- metabolizable membrane-protectant sugar; and a specifically defined pH buffering system. Improved methods for preserving red blood cells and methods for increasing the viability, membrane retention, and recoverability while suppressing apoptosis, hemolysis, and post-reinfusion clearance of stored red blood cells which utilize the novel compositions.